Research and Markets: Hypertension - Pipeline Review, H2 2013

Business Wire

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/htmrgs/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2013" report to their offering.

This report provides information on the therapeutic development for Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypertension.

Scope

  • A snapshot of the global therapeutic scenario for Hypertension.
  • A review of the Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hypertension pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • News and deals relating to the products.

Reasons to Buy

  • Identify and understand important and diverse types of therapeutics under development for Hypertension.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

  • AFFiRiS
  • Ache Laboratorios Farmaceuticos
  • Ahn-Gook Pharmaceutical Co.
  • Anacor Pharmaceuticals
  • AngioDesign
  • BioLineRx
  • Biocon Limited
  • Biolink Group
  • Cellceutix Corporation
  • Chong Kun Dang Pharmaceutical
  • Choongwae Pharma Corp
  • Compugen
  • Cytokinetics
  • DONGKOOK Pharmaceutical Co.
  • Daewoong Pharmaceutical Co.
  • Daiichi Sankyo Company
  • DiaMedica
  • Diakron Pharmaceuticals
  • GlaxoSmithKline
  • Hanall Pharmaceutical Co.
  • INNOPHARMAX
  • IntelGenx Technologies Corp.
  • Kotobuki Pharmaceutical Co.
  • LG Life Sciences
  • Medivir
  • Merck & Co.
  • MicroDose Therapeutx
  • miRagen Therapeutics
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis
  • Palatin Technologies
  • Panacea Biotec
  • QUANTUM GENOMICS Corp.
  • Samyang Corporation
  • Sanofi-Aventis
  • Shionogi & Co.
  • Sihuan Pharmaceutical Holdings Group
  • Takeda Pharmaceutical Company
  • Torrent Pharmaceuticals
  • Vicore Pharma
  • Yuhan Corporation
  • vasopharm

For more information visit http://www.researchandmarkets.com/research/htmrgs/hypertension

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular

Rates

View Comments (0)